DK0828758T3 - Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering - Google Patents

Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering

Info

Publication number
DK0828758T3
DK0828758T3 DK96914826T DK96914826T DK0828758T3 DK 0828758 T3 DK0828758 T3 DK 0828758T3 DK 96914826 T DK96914826 T DK 96914826T DK 96914826 T DK96914826 T DK 96914826T DK 0828758 T3 DK0828758 T3 DK 0828758T3
Authority
DK
Denmark
Prior art keywords
grf
pro
chimeric
grf analogs
adipose
Prior art date
Application number
DK96914826T
Other languages
Danish (da)
English (en)
Inventor
Michel Ibea
Paul Brazeau
Thierry Abribat
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0828758(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Application granted granted Critical
Publication of DK0828758T3 publication Critical patent/DK0828758T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
DK96914826T 1995-05-26 1996-05-22 Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering DK0828758T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
DK0828758T3 true DK0828758T3 (da) 2002-01-07

Family

ID=27036979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96914826T DK0828758T3 (da) 1995-05-26 1996-05-22 Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering

Country Status (13)

Country Link
US (2) US5861379A (de)
EP (1) EP0828758B1 (de)
JP (1) JP3576170B2 (de)
KR (1) KR100543190B1 (de)
AT (1) ATE204881T1 (de)
AU (1) AU697119B2 (de)
BR (2) BRPI9608799B8 (de)
CA (1) CA2222068C (de)
DE (1) DE69614849T2 (de)
DK (1) DK0828758T3 (de)
ES (1) ES2163020T3 (de)
PT (1) PT828758E (de)
WO (1) WO1996037514A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
EP1052286A3 (de) * 1999-04-12 2001-07-25 Pfizer Products Inc. Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
EP1305338A2 (de) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modifizierte peptide mit erhöhter wirksamkeit
EP1205551A1 (de) * 2000-11-09 2002-05-15 Pfizer Products Inc. Wachstumshormon- (GH) und Wachstumshormon-freisetzenden Hormon (GHRH) enthaltende Zusammensetzungen
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
CN102861321A (zh) 2003-09-12 2013-01-09 特西卡股份有限公司 胰岛素样生长因子-1(igf-1)缺陷的治疗方法
AU2004281084B2 (en) * 2003-10-20 2010-08-12 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP2421547A1 (de) * 2009-04-20 2012-02-29 Theratechnologies Inc. Verwendung von (hexenoyl-trans-3)hgrf(1-44)nh2 und ritonavir in einer kombinationstherapie
EP2421548A4 (de) * 2009-04-20 2012-09-26 Theratechnologies Inc Verwendung von (hexenoyl-trans-3)hgrf(l-44)nh2 und simvastatin in einer kombinationstherapie
RU2016111360A (ru) 2010-08-13 2018-11-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
WO2012037519A2 (en) * 2010-09-16 2012-03-22 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
JP6113144B2 (ja) 2011-04-21 2017-04-12 セラテクノロジーズ・インコーポレーテッド 成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109153712B (zh) 2016-04-19 2022-09-16 格里芬制药国际公司 Peg化生物活性肽及其用途
WO2024091863A1 (en) * 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated peptides that release growth hormone and their use
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
BRPI9608799B8 (pt) 2019-11-05
KR19990021938A (ko) 1999-03-25
CA2222068A1 (en) 1996-11-28
WO1996037514A1 (en) 1996-11-28
PT828758E (pt) 2002-02-28
JP3576170B2 (ja) 2004-10-13
CA2222068C (en) 2007-04-10
EP0828758B1 (de) 2001-08-29
EP0828758A1 (de) 1998-03-18
JPH11505807A (ja) 1999-05-25
BR9608799A (pt) 1999-12-07
US5939386A (en) 1999-08-17
DE69614849T2 (de) 2002-05-16
US5861379A (en) 1999-01-19
KR100543190B1 (ko) 2006-06-23
BR9608799B1 (pt) 2009-12-01
AU697119B2 (en) 1998-09-24
ATE204881T1 (de) 2001-09-15
MX9709098A (es) 1998-06-30
DE69614849D1 (de) 2001-10-04
AU5683396A (en) 1996-12-11
ES2163020T3 (es) 2002-01-16

Similar Documents

Publication Publication Date Title
DK0828758T3 (da) Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
MX9204861A (es) Analogos de polipeptidos que tienen actividad liberadora de la hormona de crecimiento.
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
DK193887D0 (da) Fysiologisk aktivt peptid
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
SE8008415L (sv) Cyklisk analog for fagocytosstimulerande naturpeptid, dvs treonyl-cyklo-(-n-lysyl-prolyl-arginyl-)
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
PL297850A1 (en) Polypeptide compounds ehibiting activity capable to release the growth hormone
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
IL85029A (en) Microcrystalline cis diammineplatinum(ii)complex of 1,1-cyclobutanedicarboxylic acid,its preparation and cytostatic pharmaceutical compositions containing it
KR920018076A (ko) 신규 폴리펩티드
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
UA19786A (uk) Засіб для обробки бульб кортоплі перед посадкою
JPS6423899A (en) Novel physiologically active polypeptide
ATE96336T1 (de) Anordnung zur selbstverabreichung physiologisch aktiver substanzen unter vorbeugung einer ueberdosierung.